Deals this week: Peakdale Molecular, Bristol-Myers Squibb, Ironwood Pharmaceuticals

29th September 2016 (Last Updated September 29th, 2016 18:30)

Peakdale Molecular and Cresset BioMolecular Discovery have entered an agreement to further expand the former’s integrated drug discovery services.

Peakdale Molecular and Cresset BioMolecular Discovery have entered an agreement to further expand the former’s integrated drug discovery services.

The agreement enables Peakdale Molecular to broaden its drug discovery platform.

Bristol-Myers Squibb and Nektar Therapeutics have entered a clinical collaboration agreement to develop a potential treatment for five tumour types and other chronic indications.

The agreement allows Bristol-Myers Squibb’s Opdivo to be used as a PD-1 immune checkpoint inhibitor to evaluate the potentiality of Nektar’s investigational immune stimulatory medicine, NKTR-214.

The partnership enables the further development of NKTR-214.

Ironwood Pharmaceuticals has raised $150 million through the private placement of 8.375% notes, due 15 September 2026. The placement has been subscribed to by TSSP and other institutional investors.

The company plans to invest the funds to pay off the principal balance of Linaclotide Pharma’s 11% notes, due in 2024.

Siegfried Holding plans to raise proceeds of up to $149.62 million through the public offering of 2.125% hybrid bonds.

UBS Investment Bank and Zurcher Kantonalbank are acting as advisors for the offering.

"Siegfried Holding plans to raise proceeds of up to $149.62 million through the public offering of 2.125% hybrid bonds."

The company will utilise the funds to repay its existing bank loans and also for capital structure management.

Array BioPharma plans for an underwritten public offering of 18.4 million shares of its common stock. The company expects to raise $115 million through the offering.

J.P. Morgan Securities and Cowen and Company are acting as joint book running managers, while Stifel Financial Corp and Wells Fargo Securities are acting as lead managers, and Gross Cutler Seiler Dupont is acting as legal advisor for the offering, which is expected to be completed by 3 October.

The company intends to use the proceeds to advance its research and development (R&D) and clinical trial programmes for general corporate purposes and to increase the working capital.


Image: Bristol-Myers Squibb and Nektar Therapeutics have entered a clinical collaboration agreement. Photo: Courtesy of Rept0n1x.